Newsletter

Subscribe and recieve updates on this company.

Text STOCKS to 72727 for mobile alerts

We are excited to present Cell Source, Inc. (OTC: CLCS).

Full DD Report for CLCS

You must become a subscriber to view this report.


Recent News from (OTC: CLCS)

Cell Source to Present at the LD Micro Main Event
LOS ANGELES, CA / ACCESSWIRE / November 16, 2015 / Cell Source, Inc. (OTCQB: CLCS), a biotechnology company focused on developing cell therapy treatments based on immunotherapy and regenerative medicine today announced that it will be presenting at the 8th annual LD Micro Main Event on Thurs...
Source: ACCESSWIRE IA
Date: November, 25 2015 14:00
Cell Source's Megadose Drug Combination Treats First Patient
NEW YORK, NY --(Marketwired - November 11, 2015) - Cell Source, Inc. (OTCQB: CLCS) a biotechnology company focused on developing cell therapy treatments based on immunotherapy and regenerative medicine, announced today initial indications that its Megadose Drug Combination has been used ...
Source: Marketwired
Date: November, 11 2015 08:51
Inaugural Scientific Advisory Board Summit JV Pharma Collaboration Initiative
NEW YORK, NY --(Marketwired - November 04, 2015) - Cell Source, Inc. (OTCQB: CLCS) a biotechnology company focused on developing cell therapy treatments based on immunotherapy and regenerative medicine, announced their initiative for joint venture Pharma collaborations at their inaugur...
Source: Marketwired
Date: November, 04 2015 09:14
Cell Source Appoints Dr. Hermann Einsele to Its Scientific Advisory Board
NEW YORK, NY --(Marketwired - September 02, 2015) - Cell Source, Inc. (OTCQB: CLCS) a biotechnology company focused on developing cell therapy treatments based on immunotherapy and regenerative medicine, announced today that Dr. Hermann Einsele, Professor of Internal Medicine and Directo...
Source: Marketwired
Date: September, 02 2015 12:00
Cell Source Appoints Dr. Dennis Brown as Chairman of Its Board of Directors
Cell Source Appoints Dr. Dennis Brown as Chairman of Its Board of Directors
Source: OTC Markets
Date: August, 19 2015 00:00

 


Last 5 Days Trading Activity

DateOpen PriceClose PriceHighLowVolume
2018-07-200.76790.76790.76790.76791,000
2018-07-19N/A0.839N/AN/A0
2018-07-180.76790.8390.8390.7679700
2018-07-17N/A0.839N/AN/A0
2018-07-16N/A0.839N/AN/A0

Last 5 Days Short Activity

DateShort VolumeTotal VolumeShort PercentageShort Indicator
2018-07-101,0001,000100.0000Short
2018-06-282,0002,10095.2381Short
2018-06-261,0001,000100.0000Short
2018-06-221,0001,10090.9091Short
2018-06-1821140052.7500Short

* Short Mode

Short Analysis provided by Squeeze Report. Get a complete short report on CLCS.


About Cell Source, Inc. (OTC: CLCS)

Logo for Cell Source, Inc. (OTC: CLCS)

We are currently conducting research and development activities in order to facilitate the transition of the patent technology we license from the laboratory to clinical trials. Our planned principal operations are the development and commercialization of new cell therapy products focused on treatment of blood cancers, nonmalignant blood disorders and organ transplantations.

 

Contact Information

 

 

Current Management

  • Itamar Shimrat / President, CEO, CFO
  • Dennis Brown / Chairman
  • Yoram Drucker /
  • Ben Friedman /
  • Itamar Shimrat /
  • David Zolty /

Current Share Structure

  • Market Cap: $9,771,702 - 03/09/2018
  • Authorized: 200,000,000 - 09/30/2016
  • Issue and Outstanding: 24,429,256 - 11/15/2016
  • Float: 5,620,428 - 04/20/2016

 


Recent Filings from (OTC: CLCS)

Notification that form 10-K will be submitted late
Filing Type: NT 10-KFiling Source: edgar
Filing Date: March, 31 2017
Quarterly report with a continuing view of a company's financial position
Filing Type: 10-QFiling Source: edgar
Filing Date: November, 18 2016
Notification that form 10-Q will be submitted late
Filing Type: NT 10-QFiling Source: edgar
Filing Date: November, 15 2016
Quarterly report with a continuing view of a company's financial position
Filing Type: 10-QFiling Source: edgar
Filing Date: August, 15 2016
Quarterly report with a continuing view of a company's financial position
Filing Type: 10-QFiling Source: edgar
Filing Date: May, 13 2016
OTCQB Certification - OTCQB Certification
Filing Type: OTCQB Certification - OTCQB CertificationFiling Source: OTC Markets
Filing Date: April, 21 2016
Annual report with a comprehensive overview of the company
Filing Type: 10-KFiling Source: edgar
Filing Date: April, 14 2016
Notification that form 10-K will be submitted late
Filing Type: NT 10-KFiling Source: edgar
Filing Date: March, 31 2016
Quarterly report with a continuing view of a company's financial position
Filing Type: 10-QFiling Source: edgar
Filing Date: November, 16 2015
Report of unscheduled material events or corporate changes.
Filing Type: 8-KFiling Source: edgar
Filing Date: November, 16 2015

 

 


Daily Technical Chart for (OTC: CLCS)

Daily Technical Chart for (OTC: CLCS)


Stay tuned for daily updates and more on (OTC: CLCS)

It most certainly could but even more important is the recent overwhelming interest in the company. Check out Investors Hub and search on Twitter

More to come on (OTC: CLCS)

Do your DD and if you choose, be ready to go!


 

The Research: All source information contained in this email is from the public sources mentioned below.

 

 
 

Thank you

OTC Report
@OTCReporter

 

 


Disclaimer: OTC Report publishes reports providing information on selected companies. OTC Report is not a registered investment advisor or broker-dealer. This report is provided as an information service only, and the statements and opinions in this report should not be construed as an offer or solicitation to buy or sell any security. OTC Report accepts no liability for any loss arising from an investors reliance on or use of this report. An investment in CLCS is considered to be highly speculative and should not be considered unless a person can afford a complete loss of investment. OTC Report has received up to $100,000 worth of crypto currency from a non-affiliated third party for the publication and circulation of this report. OTC Report does not own any shares of CLCS and does not buy, sell, or trade any shares of CLCS. This report contains forward-looking statements, which involve risks, and uncertainties that may cause actual results to differ materially from those set forth in the forward-looking statements. Copyright 2018 by OTC Report. All rights reserved. Our Full Disclaimer: http://otc.report/disclaimer/